Origin: From a cross of a Bagg albino female and a DBA male by Strong in 1920. The CBA strain was selected for a low mammary tumour incidence. Transferred via The Jackson Laboratory to Haldane and Gruneberg in 1932. To Carter (CBA/Ca) in 1947. VAF/Plus breed stock to Charles River Laboratories UK from Glaxo in 1992.
MHC haplotype: H-1a, H-2k, H-3
Ideal for: Research applications include brain development, neurochemistry and behavioural studies
Bred in: UK
Health reports: Using strain nomenclature find the strain at links below
*Images courtesy of Charles River